Loading
Loading
Research Overview
11-amino-acid peptide derived from the prohormone region of preprodopamine; proposed direct neurotrophic action on dopaminergic neurons in preclinical Parkinson's-model paradigms via mechanisms not fully characterised.
DNSP-11 is a short peptide sequence found in the prohormone region of the dopamine precursor preprodopamine. Preclinical research has investigated whether this naturally-derived sequence possesses neurotrophic or neuroprotective properties toward dopaminergic neurons — the neuronal population that degenerates in Parkinson's disease.
Animal model research has used dopaminergic neurotoxicity paradigms (such as 6-OHDA and MPTP models) to examine whether DNSP-11 administration affects dopaminergic neuron survival, dopamine turnover, and behavioural outcomes related to motor function. The proposed mechanism involves direct neurotrophic action on dopaminergic cell populations.
DNSP-11 is a highly experimental compound with no standardised human dosing protocol and no published human safety data. Its extremely short plasma half-life (minutes) and the use of intracranial routes in some animal studies present significant barriers to translational research.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, dnsp-11 has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
DNSP-11 research is most relevant to protocols examining:
Dopaminergic neuron protection and Parkinson's disease model research
Preprodopamine-derived peptide biology studies
Neurotrophic mechanism investigations in dopamine system
Researchers studying novel peptide approaches to dopaminergic neuroprotection
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: Minutes (plasma)). Review data, confirm baseline recovery before any repeat protocol.
11-amino-acid peptide derived from the prohormone region of preprodopamine; proposed direct neurotrophic action on dopaminergic neurons in preclinical Parkinson's-model paradigms via mechanisms not fully characterised.
| Parameter | Value |
|---|---|
| Dose range | No human protocol established |
| Schedule | Animal models only |
| Route | Subcutaneous |
| Half-life | Minutes (plasma) |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.